Arap and Pasqualini Join Oncology Leadership at Rutgers Cancer Institute of New Jersey
The Rutgers Cancer Institute of New Jersey has announced 2 new additions to its team of oncology leaders. Wadih Arap, MD, PhD, will serve as the new director of the Rutgers Cancer Institute of New Jersey at University Hospital, and Renata Pasqualini, PhD, will serve as the chief of the Division of Cancer Biology in the Department of Radiation Oncology at Rutgers New Jersey Medical School.
Wadih Arap, MD, PhD, and Renata Pasqualini, PhD
Wadih Arap, MD, PhD, and Renata Pasqualini, PhD
The Rutgers Cancer Institute of New Jersey has announced 2 new additions to its team of oncology leaders. Wadih Arap, MD, PhD, will serve as the new director of the Rutgers Cancer Institute of New Jersey at University Hospital, and Renata Pasqualini, PhD, will serve as the chief of the Division of Cancer Biology in the Department of Radiation Oncology at Rutgers New Jersey Medical School.
Arap has worked as the Chief of Hematology/Oncology Division and as Deputy Director at the University of New Mexico Comprehensive Cancer Center. Assuming the director position from Susan Goodin, PharmD, who served in an interim capacity, Arap will also be taking on the role of chief in the Division of Hematology/Oncology in the Department of Medicine at Rutgers New Jersey Medical School.
Rutgers Cancer Institute Director Steven K. Libutti, MC, FACS, spoke about what is expected when Arap joins the team. “Under his leadership, opportunities will be developed to reduce cancer incidence and improve patient outcomes through enhanced clinical services and research.”
Arap plans to build on the partnership goals to enhance clinical trial access in the region and expand the community outreach and education.
Pasqualini has previously served as Associate Director for Translational Research and Chief of the Division of Molecular Medicine at the University of New Mexico Comprehensive Cancer Center. She also held a leadership position during her 14-year tenure at The University of Texas MD Anderson Cancer Center.
The husband-and-wife duo led a joint laboratory program for 20 years. They have made groundbreaking discoveries on the diversity of blood vessels in normal and diseased organs. These discoveries have included identifying different molecular signatures based on their locations in the body. These “vascular ZIP codes” can be used to selectively deliver therapeutic and diagnostic agents in a variety of diseases, including cancer.
Arap and Pasqualini have published more than 200 joint peer-reviewed research manuscripts together and have more than 100 patents filed worldwide. They hope to bring important advances to science and medicine to the Rutgers Cancer Institute of New Jersey at the University Hospital in Newark as they integrate new research and drug development efforts.
Rutgers Cancer Institute of New Jersey offers the most advanced cancer treatment options including clinical trials and novel therapeutics. Patients receive access to these cutting-edge therapies throughout the state at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, and RWJBarnabas Health.
University Hospital is an independent medical center located in Newark, New Jersey. It is the designated Level 1 Trauma Center for Northern New Jersey, maintaining 24-hour in-house coverage by general surgeons and prompt care in specialties such as orthopedic surgery, neurosurgery, internal medicine, plastic surgery, and pediatrics.
